The Pioneer Behind the Ballast Pick
Porter Stansberry’s Ignition Point pitch is built around silencing the gene that produces lipoprotein(a), or Lp(a). The “Ballast” pick in that pitch is Novartis, and the drug at the center of it is pelacarsen. What the pitch does not emphasize is that pelacarsen was not invented at Novartis. It was built by Ionis Pharmaceuticals (IONS), the antisense pioneer that licensed the drug to Novartis years ago.
That relationship is the quiet thread running through the entire gene-silencing story. Ionis has spent decades developing antisense technology, a way to block the messenger RNA that a gene uses to build a protein. It is a close cousin of the RNAi approach that won the 2006 Nobel Prize, and it sits at the root of several drugs that larger companies now sell.
How Antisense Works
Antisense drugs are short, synthetic pieces of genetic material designed to bind to a specific messenger RNA and stop it from producing a protein. For Lp(a), the target is the messenger RNA that builds apolipoprotein(a), the key component of the Lp(a) particle. Block that message, and the body makes less Lp(a).
Ionis built pelacarsen around this idea, then handed the late-stage work to Novartis under a license. Novartis took on the big cardiovascular outcomes trial, while Ionis retained milestone and royalty economics on the drug. That is the classic biotech division of labor: one company invents, another finances and runs the expensive final test.
The September 2026 Setback
The teardown of Ignition Point surfaces a hard fact. On September 4, 2026, Novartis reported that pelacarsen failed its cardiovascular endpoint. The drug lowered the Lp(a) biomarker, but it did not reduce heart attacks, strokes, or other events. For a drug built to prove that lowering Lp(a) saves lives, that is the one result that matters.
Ionis still collects royalties on pelacarsen if it sells, but the commercial ceiling is now far lower than the thesis assumed. The failure also hangs over the entire antisense approach to Lp(a), and it raises the bar for the RNAi competitors chasing the same target, which we frame in our Amgen piece.
A Platform, Not a Single Bet
The reason Ionis matters beyond pelacarsen is its platform. The company has pushed multiple antisense drugs through development, and its pipeline spans cardiovascular disease, neurology, and rare conditions. A single endpoint failure hurts, but it does not define a company whose technology keeps producing candidates.
That is the difference between a developer and a royalty collector. Ionis invents and licenses, which means it carries more science risk than the pure tollbooth names in Porter’s barbell, but it also captures more upside when a drug works. We explore that capital-light side in his Royalty Riches teardown.
What to Watch
The near-term question for Ionis is whether any of its other late-stage programs can deliver the outcome that pelacarsen could not. The company’s value leans on its ability to keep converting antisense technology into partnered drugs, and the market will judge that pipeline one readout at a time.
For investors watching the Lp(a) race, Ionis is the reminder that the science behind a blockbuster drug rarely belongs to the company selling it. Understanding who invented what is often the difference between buying the story and buying the royalty.
Antisense Versus RNAi
Antisense and RNAi are two routes to the same destination. Both try to stop a gene from making its protein, but they go about it differently. Antisense drugs use a synthetic strand that binds to messenger RNA and blocks it directly. RNAi uses a small interfering RNA that recruits the cell’s own machinery to destroy the messenger RNA instead.
Ionis is the standard-bearer of the antisense camp, and pelacarsen is its signature Lp(a) program, licensed to Novartis. The RNAi side includes Alnylam, the company Porter calls the “Anchor” pick, plus Arrowhead and the lepodisiran program that Eli Lilly took over from Dicerna. The two camps are racing toward the same endpoint, and the September 2026 pelacarsen failure handed the antisense side a setback that the RNAi names are now trying to capitalize on.
For Ionis, the distinction matters because it frames the company’s value. It is not a one-drug bet but a platform company that has been inventing antisense medicines for decades, licensing many of them to larger partners. A single endpoint miss is painful, but it does not erase the platform that produced it.
The question for investors is whether the platform can keep producing, and whether the next partnered drug can deliver the outcome pelacarsen could not. That is the bet behind the antisense pioneer.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.